In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib
versus treatment with lomustine in patients with recurrent glioblastoma multiforme. The
investigators hypothesize that sunitinib, when given in a high-dose, intermittent schedule,
will achieve adequate concentration levels in the tumor and will, besides its anti-angiogenic
properties, inhibit gliomagenesis by inhibition of multiple kinases.